Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib with Neoadjuvant Radiation in Soft-tissue Sarcoma
NCT00753727Phase 2Unknown
- Sponsor
- Australia and New Zealand Sarcoma Association
- Start
- Sep 2008
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in soft tissue sarcoma (STS), sponsored by Australia and New Zealand Sarcoma Association. Primary endpoint: Maximum Tolerated Dose. Status: unknown.
02
Drugs
sunitinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT00753727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00753727.